Q-omics provides the consensus-scored GALNT9 profile across patient tissues and cancer cell-line models. GALNT9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GALNT9 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, GALNT9 RNA expression shows 15,210 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where GALNT9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT9 survival associations across molecular data types. GALNT9 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT9 RNA expression–survival associations across cancer types. High GALNT9 expression shows unfavorable associations in ACC, OV and BLCA, but favorable associations in HNSC, LGG and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GALNT9 RNA expression.
This table summarizes GALNT9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GALNT9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT9 shows lower tumor expression in THCA, KIRP, KICH and UCEC and higher tumor expression in HNSC and CHOL. The THCA box plot shows higher GALNT9 RNA expression in normal versus tumor tissue (log2 FC = −3.056, t-test p < 0.001).
This table shows molecular features associated with GALNT9 in patient tissues and cancer cell lines. In patient samples, GALNT9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
